The new WHO classification of adrenal cortical proliferations reflects translational advances
in the fields of endocrine pathology, oncology and molecular biology. By adopting a …

Adrenocortical carcinoma (ACC) is an aggressive and rare neoplasm that originates in the
cortex of the adrenal gland. The disease is associated with heterogeneous but mostly poor …

Background Adjuvant treatment with mitotane is commonly used after resection of
adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of …

Adrenocortical carcinoma (ACC) accounts for a minority of all malignant tumors in adults.
Surgery remains the most important therapeutic option for non-metastatic ACC. Whether a …

Approximately one-tenth of the general population exhibit adrenal cortical nodules, and the
incidence has increased. Afflicted patients display a multifaceted symptomatology …

Adrenocortical carcinoma (ACC) is an aggressive cancer characterized by poor survival.
Apart from radical surgery, there is a limited range of therapeutic options and mitotane …

Background Adrenocortical carcinoma (ACC) is an aggressive and rare malignant tumor
and is prone to local invasion and metastasis. And, overexpressed Centromere Protein F …

Adrenocortical carcinoma is a rare malignancy with an annual worldwide incidence of 1–2
cases per 1 million and a 5-year survival rate of< 60%. Although adrenocortical carcinoma is …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …

Aging markedly increases cancer risk, yet our mechanistic understanding of how aging
influences cancer initiation is limited. Here we demonstrate that the loss of ZNRF3, an …